How often should women take the HIV prevention pill? a new study aims to find out
NCT ID NCT05057858
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how often cisgender women in Kenya need to take the HIV prevention pill Truvada (TDF-FTC) to keep protective drug levels in their blood. Participants are randomly assigned to take 2, 4, or 7 doses per week for up to 16 weeks, and their drug levels are measured. The study also explores how pregnancy may affect these levels, to help guide PrEP dosing recommendations for pregnant women.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Truvada (tenofovir disoproxil fumarate and emtricitabine)
What this could lead to
If successful, this study could help define the optimal dosing schedule for oral PrEP to prevent HIV in cisgender women, including during pregnancy.
What could go wrong
This is a small Phase 2 study focused on drug levels, not on actual HIV prevention outcomes. Results may not translate to real-world adherence or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kenya Medical Research Institute - Partners in Health Research and Development
Thika, Kenya